Denali Therapeutics Inc. - COMMON STOCK (DNLI)

CUSIP: 24823R105

Q4 2017 13F Holders as of 31 Dec 2017

Type / Class
Equity / COMMON STOCK
Shares outstanding
147,179,178
Total 13F shares
58,144,510
Share change
+58,037,844
Total reported value
$909,309,000
Price per share
$15.64
Number of holders
45
Value change
+$907,640,000
Number of buys
43

Quarterly Holders Quick Answers

What is CUSIP 24823R105?
CUSIP 24823R105 identifies DNLI - Denali Therapeutics Inc. - COMMON STOCK in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q4 2017

As of 31 Dec 2017, Denali Therapeutics Inc. - COMMON STOCK (DNLI) was held by 45 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 58,144,510 shares. The largest 10 holders included Crestline Management, LP, FMR LLC, Flagship Pioneering Inc., BAILLIE GIFFORD & CO, Temasek Holdings (Private) Ltd, FIL Ltd, Vanguard Group Inc, NORGES BANK, Alphabet Inc., and Mitsubishi UFJ Trust & Banking Corp. This page lists 45 institutional shareholders reporting positions in this security for the Q4 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.